Who are QLM3004 Concentration 3's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SINECATECHINS, PODOFILOX, POLIDEXIDE SULFATE, SUTILAINS, BNT162b2 (Omi JN.1), Top-down.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/qlm3004-concentration-3.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

QLM3004 Concentration 3 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

QLM3004 Concentration 3 (QLM3004 Concentration 3) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: unknown. Area: unknown.

phase 3 unknown unknown unknown Small molecule Live · refreshed every 30 min

Target snapshot

QLM3004 Concentration 3 (QLM3004 Concentration 3) — Qilu Pharmaceutical Co., Ltd.. QLM3004 Concentration 3 is a drug that works by inhibiting the activity of a specific molecular target.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
QLM3004 Concentration 3 TARGET	QLM3004 Concentration 3	Qilu Pharmaceutical Co., Ltd.	phase 3	unknown	unknown
SINECATECHINS	SINECATECHINS		marketed	Polyphenols	Unknown	2006-01-01
PODOFILOX	PODOFILOX		marketed	Topical antiviral	Unknown	1990-01-01
POLIDEXIDE SULFATE	POLIDEXIDE SULFATE		marketed	Unknown	Unknown	1974-01-01
SUTILAINS	SUTILAINS		marketed	Unknown	Unknown	1969-01-01
BNT162b2 (Omi JN.1)	bnt162b2-omi-jn-1	Pfizer	marketed	unknown	unknown
Top-down	Top-down	University of Roma La Sapienza	marketed	small molecule	unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-10-02 — SINECATECHINS · 7858662 · Formulation · US

Sponsor landscape (unknown class)

Pfizer · 7 drugs in this class
Pfizer Inc. · 3 drugs in this class
Qilu Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). QLM3004 Concentration 3 — Competitive Intelligence Brief. https://druglandscape.com/ci/qlm3004-concentration-3. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing